THU-486 The anticoagulant Edoxaban improves portal hypertension and liver injury in progressive liver disease
Katharina Bonitz(Austrian Academy of Sciences), Benedikt Hofer(Austrian Academy of Sciences), Philipp Schwabl(Austrian Academy of Sciences), Hubert Scharnagl(Medical University of Graz), Oleksandr Petrenko(Austrian Academy of Sciences), Thomas Reiberger(ERN GUARD-Heart), Henriette Horstmeier, Thomas Sorz‐Nechay(Austrian Academy of Sciences), Georg Kramer(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Kerstin Zinober(Medical University of Vienna), Vlad Țâru(Iuliu Hațieganu University of Medicine and Pharmacy)
Cited by 0
Related Papers
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
|Journal of Hepatology|2020|202
Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
|Clinical Gastroenterology and Hepatology|2022|130
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis
|Nature Protocols|2015|119